These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 33854987)

  • 1. NAFLD-Associated HCC: Progress and Opportunities.
    Geh D; Anstee QM; Reeves HL
    J Hepatocell Carcinoma; 2021; 8():223-239. PubMed ID: 33854987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
    Streba LA; Vere CC; Rogoveanu I; Streba CT
    World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.
    Geh D; Manas DM; Reeves HL
    Hepatobiliary Surg Nutr; 2021 Jan; 10(1):59-75. PubMed ID: 33575290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link.
    Chrysavgis L; Giannakodimos I; Diamantopoulou P; Cholongitas E
    World J Gastroenterol; 2022 Jan; 28(3):310-331. PubMed ID: 35110952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging risk factors for nonalcoholic fatty liver disease associated hepatocellular carcinoma.
    Benhammou JN; Lin J; Hussain SK; El-Kabany M
    Hepatoma Res; 2020; 6():. PubMed ID: 32685690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular Carcinoma Screening and Nonalcoholic Fatty Liver Disease: How is it Different?
    Acharya SK; Bopanna S
    J Clin Exp Hepatol; 2020; 10(5):518-524. PubMed ID: 33029058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal Metabolism in the Progression of Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma: Mechanistic Insights to Chemoprevention.
    Orabi D; Berger NA; Brown JM
    Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention.
    Baffy G
    J Clin Transl Hepatol; 2013 Dec; 1(2):131-7. PubMed ID: 26355775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications.
    Wong SW; Ting YW; Chan WK
    JGH Open; 2018 Oct; 2(5):235-241. PubMed ID: 30483595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review.
    Zaman CF; Sultana J; Dey P; Dutta J; Mustarin S; Tamanna N; Roy A; Bhowmick N; Khanam M; Sultana S; Chowdhury S; Khanam F; Sakibuzzaman M; Dutta P
    Cureus; 2022 Sep; 14(9):e29657. PubMed ID: 36320966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Overview of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Management].
    Kim SK; Kim KI; Kim SR
    Yakugaku Zasshi; 2019; 139(9):1147-1153. PubMed ID: 31474630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
    Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
    Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Growing Landscape of NAFLD-Associated Hepatocellular Carcinoma and Its Impact in Surveillance.
    Machado MV
    GE Port J Gastroenterol; 2024 Feb; 31(1):14-23. PubMed ID: 38314031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges.
    Teng YX; Xie S; Guo PP; Deng ZJ; Zhang ZY; Gao W; Zhang WG; Zhong JH
    J Clin Transl Hepatol; 2022 Oct; 10(5):955-964. PubMed ID: 36304509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular carcinoma in patients with metabolic dysfunction-associated fatty liver disease: Can we stratify at-risk populations?
    Fassio E; Barreyro FJ; Pérez MS; Dávila D; Landeira G; Gualano G; Ruffillo G
    World J Hepatol; 2022 Feb; 14(2):354-371. PubMed ID: 35317172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 20.  Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries.
    Seyda Seydel G; Kucukoglu O; Altinbasv A; Demir OO; Yilmaz S; Akkiz H; Otan E; Sowa JP; Canbay A
    Ann Hepatol; 2016; 15(5):662-72. PubMed ID: 27493104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.